UNSPSC 51286204: Fosfomycin disodium

This classfication denotes a urinary anti-infective agent with the molecular formula C3H5O4P.2Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 97MMO19FNO, chemically known as disodium (2r,3s)-3-methyloxiran-2-ylphosphonate, but more generally known as fosfomycin disodium, which bears US NIH Compound Identifier 3417. European Medicines Agency schedules fosfomycin disodium or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07797MIG.

Most nations, for tariff purposes, schedule fosfomycin disodium under HS 29419000. SMILES: C[C@H]1[C@H](O1)P(=O)([O-])[O-].[NA+].[NA+].

UNSPSC 51286204 Fosfomycin disodium is a Commodity code with minimal direct alignment to recent state and local procurement activity. The code nominally describes a specific antibiotic pharmaceutical product, but the recent opportunities tagged to it span naloxone and drug deactivation systems, medical and first-aid supplies for emergency response, generic multi-source pharmaceuticals and OTC products through cooperative purchasing, and a request for information on direct-to-manufacturer prescription programs. None of these solicitations center on fosfomycin disodium as a discrete product line, and the code shows little evidence of active, focused procurement under its stated scope. State and local issuing bodies appear to source pharmaceutical and medical supplies through broader categorical procurements—cooperative purchasing vehicles, emergency medical supply contracts, and pharmacy benefit program initiatives—rather than through single-drug commodity codes.

The geographic spread of recent activity involves Florida (Seminole County), Texas (HHS Commission), Minnesota and Oregon (MMCAP cooperative), and Florida again (City of Tampa), reflecting isolated, episodic opportunities rather than concentrated demand. The representative recent solicitations—Seminole County IFB for naloxone and drug deactivation systems (due July 26, 2023), City of Tampa IFB for medical and first-aid supplies estimated at $700,000 (due March 13, 2026, SLBE-sheltered), MMCAP RFP for generic multi-source pharmaceuticals and OTC products (due March 26, 2026), and Texas HHS RFI on direct-to-manufacturer prescriptions (due April 3, 2026)—demonstrate that state and local governments procure pharmaceuticals and medical supplies through multi-line aggregated contracts and cooperative purchasing frameworks rather than by individual drug product. The code itself does not appear to reflect how procurement offices actually organize and solicit pharmaceutical inventories at the state and local level, making it of limited relevance for targeted business development.